You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Chemically controlling chromatin to treat Friedriech's Ataxia

    SBC: Epigenos Bioscience, Inc.            Topic: NCATS

    We recently developed a technology that combines catalytically inactive dCas9 with bifunctional chemicals that link endogenous host cellular machinery to specific genes targeted with dCas9. We have demonstrated this technology can significantly increase gene expression at multiple endogenous mammalian genes in a chemically dependent manner. Here we propose to apply this technology to the mono-alle ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD

    SBC: SAMAY, INC.            Topic: NHLBI

    ABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Continuum Actuated Redundant Tendon Robots

    SBC: OPTERUS RESEARCH AND DEVELOPMENT, INC            Topic: HR001119S003523

    Opterus Research and Development, Inc. (Opterus) and Colorado State University (CSU) have combined the best features of high strain composites (HSC), continuum robots, and tendon actuated robots to develop a new concept called Continuum Actuated Redundant Tendon (CART) Robot to enable self-reconfigurable modular robots that can perform various tasks (e.g., walking, crawling, wheeling, and grasping ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
  4. Detection of perfuorooctanoic acid (PFOA) and perfluorooctane sulfonate(PFOS) in liquid samples.

    SBC: SEACOAST SCIENCE, INC.            Topic: NIEHS

    Perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion

    SBC: Bedrock Therapeutics, Inc.            Topic: NHLBI

    Adeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with hemophilia. Two AAV based gene therapy drugs have been recently approved by the FDA. Luxturna has been valued at $850,000 for a one-time treatment for a rare form of blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. Gene therapy with AAV vectors has shown a potentially huge market ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas

    SBC: NEONC TECHNOLOGIES INC            Topic: 102

    Despite important advances in surgical techniques, imagistic modalities and computer-assisted stereotactic delivery of radiation therapy, the prognosis for patients with glioblastoma (GB) remains grim and has not significantly changed in decades. The Stupp protocol—i.e., concurrent temozolomide (TMZ) plus conformal external beam radiotherapy (EBRT) followed by adjuvant TMZ—remains the cornerst ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements

    SBC: PASCALL Systems, Incorporated            Topic: NIDA

    PROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias

    SBC: Whiplash Technology, Inc.            Topic: NIA

    PROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis

    SBC: Arrevus, Inc.            Topic: NIAID

    PROJECT SUMMARYSepsis is a life-threatening syndrome that involves a systemic inflammatory response that is initiated by an infection. There are an estimated 1.5 million of cases annually in the US with 250,000 resulting in death. The number of cases and associated deaths is expected to increase given the rising at-risk population of elderly individuals and the compounding challenge of antibiotic ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia

    SBC: BRIDGENE BIOSCIENCES INC            Topic: 102

    PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government